San Diego Union-Tribune

SUIT THREATENS ABORTION PILL ACCESS

Texas judge’s ruling could halt drug’s supply nationwide

- BY LINDSAY WHITEHURST

A Texas lawsuit with a key deadline this month is posing a threat to the nationwide availabili­ty of medication abortion, which now accounts for the majority of abortions in the U.S.

The case filed by abortion opponents who helped challenge Roe v. Wade seeks to reverse a decades-old approval by the Food and Drug Administra­tion.

If a federal judge appointed by former President Donald Trump sides with them, it could halt the supply of the drug mifepristo­ne in all states, both where abortion is banned and where it remains legal.

“It could have an immediate impact on the country,” said Mini Timmaraju, president of NARAL Pro-Choice America. “In some ways this is a backdoor ban on abortion.”

On Friday, a group of 22 Democratic-led states stepped into the case, saying the consequenc­es of reversing the approval could be “nothing short of catastroph­ic.”

U.S. District Judge Matthew Kacsmaryk has not indicated when or how he will rule, but groups like Timmaraju’s have been preparing for a possible decision shortly after a Feb. 24 filing deadline. There is scant precedent for a lone judge overruling the FDA’s scientific decisions. A swift appeal of any ruling is likely.

The lawsuit was filed by the group Alliance Defending Freedom, which was also involved in the Mississipp­i case that led to Roe v. Wade being overturned.

“Our representa­tives in Congress created the FDA and gave the FDA the responsibi­lity to make sure that drugs are safe before they’re allowed on the market ... the FDA failed that responsibi­lity,” said Julie Blake, senior counsel for the group.

They argue the FDA oversteppe­d its authority in approving mifepristo­ne by using an accelerate­d review process reserved for drugs to treat “serious or lifethreat­ening illnesses.”

But in its legal response, the agency said it didn’t accelerate the drug’s approval, which came four years after the manufactur­er first submitted its applicatio­n to market the pill.

The FDA approved mifepristo­ne — in combinatio­n with a second drug — as a safe and effective method for ending a pregnancy in 2000. Common side effects include cramping and light bleeding. Cases of more severe bleeding requiring emergency care are rare.

Halting access to the drug more than 20 years after approval would be “extraordin­ary and unpreceden­ted,” federal attorneys stated in a legal filing.

Kacsmaryk, who previously ruled against a program providing free birth control to minors in Texas, could also issue a ruling rolling back regulators’ decisions to ease restrictio­ns on the pill’s availabili­ty. Those have been based on scientific studies showing women can safely use the drug at home.

In late 2021, the FDA removed a requiremen­t that women pick up the drug in person. Last month the agency dropped another requiremen­t that prevented most pharmacies from dispensing the pill.

Medication abortion accounted for over half of abortions before Roe v. Wade was overturned, according to research from the Guttmacher Institute. It’s grown more important since then, said Elizabeth Nash, state policy analyst for the sciencebas­ed research group that supports abortion rights.

“The clinics that are open in the receiving states are stretched thin, they don’t have a lot of give in their capacity and being able to provide medication abortion is very, very important,” she said.

 ?? JOSE LUIS MAGANA AP FILE ?? Abortion-rights activists set up an abortion pills educationa­l booth as they protest outside the Supreme Court in Washington.
JOSE LUIS MAGANA AP FILE Abortion-rights activists set up an abortion pills educationa­l booth as they protest outside the Supreme Court in Washington.

Newspapers in English

Newspapers from United States